Selective Interleukin-6 Trans-Signaling Blockade Is More Effective Than Panantagonism in Reperfused Myocardial Infarction
Year: 2021
Type: article
Abstract: Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatory effects. The novel recombinant fusion protein sgp130Fc achieves exclusive trans-signaling blockade, whereas anti-IL-6 antibodies (Abs) result in panantagonism. In a rat model of reperfused MI, sgp130Fc, but not anti-IL-6-Ab, attenuated neutrophil and macrophage infiltration into the myocardium, reduced infarct size, and preserved cardiac function 28 days after MI. These data demonstrate the efficacy of exclusive IL-6 trans-signaling blockade and support further investigation of sgp130Fc as a potential novel therapy in MI.
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,400
Awards: An intravital model to study mechanisms of leukocyte recruitment in experimental crescentic glomerulonephritis (CrGN), Tracking hydrogel therapeutics using quantitative whole-body imaging, The efficacy of Interleukin-6 trans-signalling blockade in attenuating inflammation and infarct size in acute myocardial infarction., The efficacy of Interleukin-6 trans-signalling blockade in attenuating inflammation and infarct size in acute myocardial infarction., Multi-spectral in vivo optical imaging system, G2970348276, G3259981160, Multi-spectral in vivo optical imaging system, BHF Centre of Regenerative Medicine (renewal), G6868616705, Image-guided cardiac regeneration: visible biomaterials functionalised to enhance stem cell-mediated repair and improve cardiac function, NIHR Senior Investigator Award
OpenAlex ID: W3144922262